Skip to main content

Advertisement

SpringerLink
Log in

The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Purpose

Acromegaly has traditionally been associated with significant mortality and cardiovascular morbidity. The aim of this study was to assess the overall mortality and improvement in mortality and morbidity in acromegaly and correlate these with cumulative growth hormone exposure.

Methods

All patients treated for acromegaly at our centre until 2012 were analysed in this retrospective observational study. Baseline demographic details such as age at diagnoses, radiological features and pituitary status were obtained on these 167 patients. Cumulative GH levels (GHy) were calculated as a sum of average of GH readings in consecutive years. Mortality rates and development of new diabetes, hypertension and cardiovascular events (stroke, congestive cardiac failure and ischaemic heart disease) were assessed.

Results

The SMR for overall cohort was 1.6. There has been a significant improvement in SMR over the past two decades (SMR until 1992 2.5; SMR since 1992 1.0). Cumulative GH exposure was significantly high in patients who died (35.2 vs 24.1, p < 0.01) and in those with incident metabolic or vascular events during follow up (51.6 vs 24.4, p = 0.0001). The cardiovascular event rate of the ‘new’ cohort was significantly better than the ‘old’ cohort (8.0 vs. 29.1 %, p < 0.001).

Conclusion

There has been significant improvement in mortality and morbidity associated with acromegaly, in the setting of routine care in a specialized endocrine unit. Early and effective treatment to ‘control’ acromegaly could reduce GH exposure and hence vascular comorbidities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90:4081–4086

    Article  PubMed  Google Scholar 

  2. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152

    Article  CAS  PubMed  Google Scholar 

  3. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R (1980) Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 12:71–79

    Article  CAS  Google Scholar 

  4. Wright AD, Hill DM, Lowy C, Fraser TR (1970) Mortality in acromegaly. Q J Med 39:1–16

    CAS  PubMed  Google Scholar 

  5. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83:3411–3418

    Article  CAS  PubMed  Google Scholar 

  6. Arita K, Kurisu K, Tominaga A, Eguchi K, Iida K, Uozumi T, Kazagi F (2003) Mortality in 154 surgically treated patients with acromegaly—a 10-year follow-up survey. Endocr J 50:163–172

    Article  PubMed  Google Scholar 

  7. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090–3098

    Article  CAS  PubMed  Google Scholar 

  8. Rolston JD, Blevins LS Jr (2012) Gamma knife radiosurgery for acromegaly. Int J Endocrinol 2012:821579. doi:10.1155/2012/821579

    Article  PubMed  PubMed Central  Google Scholar 

  9. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171–1177

    Article  CAS  PubMed  Google Scholar 

  10. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89:1613–1617

    Article  CAS  PubMed  Google Scholar 

  11. Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58:86–91

    Article  Google Scholar 

  12. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667–674

    Article  CAS  PubMed  Google Scholar 

  13. Bates AS, Van’t Hoff W, Jones JM, Clayton RN (1993) An audit of outcome of treatment in acromegaly. Q J Med 86:293–299

    CAS  PubMed  Google Scholar 

  14. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93:61–67

    Article  CAS  PubMed  Google Scholar 

  15. Jenkins D, O’Brien I, Johnson A, Shakespear R, Sheppard MC, Stewart PM (1995) The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. Clin Endocrinol (Oxf) 43:517–522

    Article  CAS  Google Scholar 

  16. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F (2004) Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 89:2789–2796

    Article  CAS  PubMed  Google Scholar 

  17. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419–3426

    CAS  PubMed  Google Scholar 

  18. Ayuk J, Sheppard MC, Clayton RN, Bates AS, Stewart PM (2004) Evidence for the use of igf-I as a predictor of mortality in acromegaly is lacking. J Clin Endocrinol Metab 89:5867–5868

    Article  CAS  PubMed  Google Scholar 

  19. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM (2001) Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357:425–431

    Article  CAS  PubMed  Google Scholar 

  20. Rosen T, Bengtsson BA (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285–288

    Article  CAS  PubMed  Google Scholar 

  21. Sherlock M, Reulen RC, Aragon-Alonso A, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2014) A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. J Clin Endocrinol Metab 99:478–485

    Article  CAS  PubMed  Google Scholar 

  22. Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K, Dhillo WS (2011) The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol (Oxf) 75:220–225

    Article  CAS  Google Scholar 

  23. Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA, Giustina A (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16:294–302

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2009) ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 94:4216–4223

    Article  CAS  PubMed  Google Scholar 

  25. Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B (1988) Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223:327–335

    Article  CAS  PubMed  Google Scholar 

  26. Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavo S, Minuto F, Montini M, Bondanelli M, De Menis E, Martini C, Angeletti G, Velardo A, Peri A, Faustini-Fustini M, Tita P, Pigliaru F, Borretta G, Scaroni C, Bazzoni N, Bianchi A, Appetecchia M, Cavagnini F, Lombardi G, Ghigo E, Beck-Peccoz P, Colao A, Terzolo M, Italian Study Group of Acromegaly (2012) Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 167:189–198

    CAS  PubMed  Google Scholar 

  27. Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730–2734

    CAS  PubMed  Google Scholar 

  28. Nachtigall L, Delgado A, Swearingen B, Lee H, Zerikly R, Klibanski A (2008) Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab 93:2035–2041

    Article  CAS  PubMed  Google Scholar 

  29. Vallette S, Ezzat S, Chik C, Ur E, Imran SA, Van Uum S, Rivera J, Caspar-Bell G, Serri O (2013) Emerging trends in the diagnosis and treatment of acromegaly in Canada. Clin Endocrinol (Oxf) 79:79–85

    Article  Google Scholar 

  30. Jayasena CN, Izzi-Engbeaya C, Narayanaswamy S, Modi M, Clarke H, Nijher GM, Meeran K, Dhillo WS (2015) Associations of coefficient of variation of serum GH with previous radiotherapy, hypopituitarism and cardiac disease in patients with treated acromegaly. Clin Endocrinol (Oxf) 82:870–875

    Article  CAS  Google Scholar 

  31. Dutta P, Hajela A, Pathak A, Bhansali A, Radotra BD, Vashishta RK, Korbonits M, Khandelwal N, Walia R, Sachdeva N, Singh P, Murlidharan R, Devgun JS, Mukherjee KK (2015) Clinical profile and outcome of patients with acromegaly according to the 2014 consensus guidelines: impact of a multi-disciplinary team. Neurol India 63:360–368

    Article  PubMed  Google Scholar 

  32. Schofl C, Grussendorf M, Honegger J, Tonjes A, Thyroke-Gronostay D, Mayr B, Schopohl J, Participants of German Acromegaly Register (2015) Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey. Eur J Endocrinol. 172:351–356

    Article  PubMed  Google Scholar 

  33. Schofl C, Franz H, Grussendorf M, Honegger J, Jaursch-Hancke C, Mayr B, Mayr B, Schopohl J, Participants of the German Acromegaly Register (2012) Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur J Endocrinol. 168:39–47

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diabetes and Endocrinology, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, ST4 6QG, UK

    Lakshminarayanan Varadhan, Maureen Brown & Richard N. Clayton

  2. Department of Public Health and Epidemiology, Centre for Childhood Cancer Survivor Studies, University of Birmingham, Birmingham, UK

    Raoul C. Reulen

Authors
  1. Lakshminarayanan Varadhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raoul C. Reulen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maureen Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard N. Clayton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lakshminarayanan Varadhan.

Ethics declarations

Conflicts of interest

Nothing to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Varadhan, L., Reulen, R.C., Brown, M. et al. The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study. Pituitary 19, 251–261 (2016). https://doi.org/10.1007/s11102-015-0700-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-015-0700-3

Keywords

Search

Navigation